On March 3, 2026, MyEyesAI participated in the NY Pitch Summit Demo Day 2026, organized by the Harvard Business School Club of New York. The event brought together a curated group of early-stage startups, investors, and innovation leaders to showcase emerging technologies and connect founders with the venture ecosystem.
Held in New York City, the Demo Day served as an interactive startup showcase where founders presented their products and engaged directly with investors, advisors, and industry leaders. For MyEyesAI, the event provided an exciting opportunity to demonstrate how artificial intelligence can expand access to preventive eye care and improve early detection of eye diseases.
Showcasing AI for Early Detection of Eye Conditions
At the event, the MyEyesAI team showcased its AI-powered platform designed to detect and analyze a wide range of eye conditions through advanced medical image analysis.
Many eye diseases—including diabetic retinopathy, glaucoma, macular degeneration, and other retinal conditions—often progress silently before symptoms appear. Early detection is critical for preventing vision loss, yet access to regular screening remains limited for millions of people worldwide.
MyEyesAI addresses this gap with an AI platform built to support broad-based eye disease detection and analysis, enabling healthcare providers and screening programs to identify potential abnormalities earlier and more efficiently.
Unlike solutions focused on a single disease, MyEyesAI is designed as a comprehensive eye health analysis platform capable of detecting indicators across multiple eye conditions. By leveraging deep learning and large datasets of retinal images, the platform can assist clinicians in scaling screening programs and improving diagnostic workflows.
During the Demo Day, attendees visited the MyEyesAI booth to learn how the platform can help health systems, clinics, and screening initiatives expand preventive eye care through AI-driven analysis.
“AI has the potential to dramatically expand access to early eye disease detection,” said Rohit Mahajan, Co-founder of MyEyesAI. “Our goal is to build a platform that can analyze eye images for a broad spectrum of conditions, helping clinicians identify risks earlier and intervene before vision loss occurs.”
Engaging with Investors and the Startup Community
The NY Pitch Summit Demo Day is part of a larger startup competition hosted by the Harvard Business School Club of New York, aimed at connecting promising startups with investors and the broader entrepreneurial community.
The event featured more than 30 startups presenting innovations across industries including healthcare, artificial intelligence, fintech, and enterprise technology. Instead of traditional stage pitches, the Demo Day used a tradeshow-style format, allowing attendees to interact directly with founders, explore product demonstrations, and have in-depth conversations about technology and business models.
For MyEyesAI, this format enabled meaningful discussions with venture capital investors, healthcare innovators, and startup advisors who were interested in the growing role of AI in healthcare diagnostics and preventive medicine.
Many conversations centered around how AI-driven screening technologies can address major healthcare challenges, including:
– Limited access to specialist care
– Rising prevalence of chronic diseases such as diabetes
– The need for scalable preventive screening programs
– Increasing demand for AI-powered clinical decision support tools
“There is growing global interest in AI solutions that enable large-scale screening and preventive healthcare,” Mahajan added. “Events like the NY Pitch Summit allow us to engage directly with investors and innovators who are equally passionate about transforming healthcare through technology.”
These discussions highlighted the strong interest in solutions that combine medical imaging, AI, and population health strategies.
Growing Momentum for AI in Ophthalmology
Artificial intelligence is rapidly transforming ophthalmology and medical imaging. AI models trained on large datasets of retinal images are increasingly being used to assist clinicians in identifying patterns that may indicate disease earlier than traditional screening approaches.
Technologies like MyEyesAI are part of a broader movement toward AI-enabled preventive healthcare, where screening and early detection can happen at scale. By supporting clinicians with intelligent image analysis, AI platforms can help reduce diagnostic workloads while improving patient outcomes.
“Vision loss from many eye diseases is preventable if detected early,” Carl Rosen, Co-founder of MyEyesAI, noted. “By applying AI to retinal imaging, we can help make early screening more accessible and scalable for health systems and communities around the world.”
During the Demo Day, attendees expressed strong interest in how MyEyesAI’s platform can support large-scale screening initiatives, particularly for populations at higher risk of eye disease such as patients with diabetes or aging populations.
Looking Ahead
Participating in the NY Pitch Summit Demo Day 2026 was an important milestone for MyEyesAI as the company continues to build partnerships across the healthcare, technology, and investment communities.
Events like this provide valuable opportunities for startups to connect with investors, receive feedback from industry experts, and build relationships that help accelerate innovation.
“Our mission is simple but ambitious—to make comprehensive AI-driven eye screening available anywhere retinal imaging can be performed,” Mahajan said. “We’re excited to continue building partnerships that help bring early detection and better eye health to more people.”
As MyEyesAI continues advancing its platform, the company remains focused on enabling earlier detection and broader analysis of eye conditions, helping expand access to preventive vision care worldwide.